Dược Lực Học :
In preclinical studies, AC220 demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).
Cơ Chế Tác Dụng :
AC220 is a small-molecule, potent inhibitor of FLT3.
AC220 potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.
Chỉ Định :
For the treatment of Acute Myeloid Leukemia (AML).